Evidence map›Paper›PMID 42131643›Full record

ArticleCureus2026

Preclinical Evaluation of Dual-Fiber Laser Ablation for Controlled Thermal Necrosis in Bovine Prostate Tissue Using the EchoLaser X4 System.

Rafael Aldaya Bourricaudy, Juan Varela, Victoria Bird

Abstract read
In one paragraph

Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Rafael Aldaya BourricaudyUrology, University of Florida College of Medicine, Gainesville, USA.
Juan VarelaUrology, University of Florida College of Medicine, Gainesville, USA.
Victoria BirdUrology, National Medical Association and Research Group, Gainesville, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction Benign prostatic hyperplasia is a common condition among aging men and a major cause of lower urinary tract symptoms that can significantly impact quality of life. The condition often leads to increased healthcare utilization and may require intervention when medical therapy is insufficient. Focal laser ablation has emerged as a minimally invasive technique that enables targeted tissue destruction while preserving surrounding structures. The EchoLaser X4 system (Elesta S.p.A., Calenzano, Florence, Italy) utilizes a dual-fiber configuration designed to optimize thermal distribution and lesion symmetry. Methods Seven bovine prostate specimens underwent ex vivo laser ablation using the EchoLaser X4 system. Two optical fibers were positioned 10 mm apart and inserted 2 cm into the tissue. Each fiber delivered up to 1000 J at 5 W. Temperature measurements were recorded at 300, 500, 800, and 1000 J. Lesion dimensions were measured in three axes, and volumes were calculated using ellipsoid geometry. Results Temperature increased in a predictable manner with escalating energy delivery, reaching mean values of 29.6°C, 37.3°C, 47.5°C, and 56.4°C at 300, 500, 800, and 1000 J, respectively. The mean necrotic volume was 2,457 mm³ (±184), with lesions demonstrating consistent ellipsoidal morphology. No evidence of thermal runaway, vaporization, or carbonization was observed. Conclusion Dual-fiber laser ablation with the EchoLaser X4 system produced controlled, reproducible tissue necrosis, supporting further investigation as a focal therapy modality for benign prostatic hyperplasia.

Indexed as

benign prostatic hyperplasiadual-fiber laserecholaser x4focal laser ablationminimally invasive urologyprostate tissuethermal ablation

Identifiers

PMID42131643
PMCPMC13163668

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.